Therapeutic strategies in the early stages of Parkinson’s disease: a cross-sectional evaluation of 15 years’ experience with a large cohort of Romanian patients

Figures & data

Figure 1 Treatment strategies as a function of age in patients diagnosed with Parkinson’s disease for less than 5 years.

Note: Numbers in columns represent number of patients.
Abbreviations: MAO-Bi, monoamine oxidase B inhibitors; DA, dopamine agonist; LD, levodopa; combined treatment, LD±DA±MAO-Bi.

Figure 2 Average treatment dose of levodopa.

Note: Chart shows mean doses and standard error of mean.
Abbreviations: LD, levodopa; LD in combination, LD±dopamine agonist± monoamine oxidase B inhibitors.

Figure 3 Treatment strategies as a function of gender in patients with Parkinson’s disease diagnosed before the age of 65 years.

Abbreviations: LD, levodopa; MAO-Bi, monoamine oxidase B inhibitors; DA, dopamine agonist; combined treatment, LD±DA±MAO-Bi.

Table 1 Summarized results

Characteristic	Value
Total: n (%)	2,379 (100%)
Men	1,249 (52.5%)
Women	1,130 (47.5%)
Average age (mean±SD)
Total	67.23±10.42 years
Time since PD diagnosis ≤5 years	65.31±10.51 years
Time since PD diagnosis ≥5 years	67.05±10.42 years
Time since PD diagnosis unknown	72.35±8.38 years
Time since PD diagnosis
≤5 years: n (%)	1,237 (52.0%)
≥5 years: n (%)	653 (27.4%)
Not known: n (%)	489 (20.6%)
Treatment strategies in case of PD diagnosed in ≤5 years
MAO-Bi monotherapy	18/1,237 (1.5%)
DA monotherapy	120/1,237 (9.7%)
LD monotherapy	521/1,237 (42.1%)
DA+MAO-Bi	83/1,237 (6.7%)
Combined treatment	481/1,237 (38.8%)
No treatment	14/1,237 (1.1%)
Average age in case of different treatment strategies
MAO-Bi monotherapy	55.21±9.25 years
DA monotherapy	59.87±11.34 years
LD monotherapy	69.01±9.04 years
DA+MAO-Bi	57.71±9.32 years
Combined treatment	64.15±9.77 years
No treatment	78.92±4.21 years

Abbreviations: PD, Parkinson’s disease; MAO-Bi, monoamine oxidase B inhibitors; DA, dopamine agonist; LD, levodopa; combined treatment, LD±DA±MAO-Bi.